Ciprofloxacin Controlled-Solid Lipid Nanoparticles: Characterization, In Vitro Release, and Antibacterial Activity Assessment

被引:45
作者
Shazly, Gamal A. [1 ,2 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmaceut, POB 2457, Riyadh 11451, Saudi Arabia
[2] Assiut Univ, Fac Pharm, Dept Ind Pharm, Assiut 71526, Egypt
关键词
DRUG-DELIVERY; FORMULATION; FLUOROQUINOLONES; VIVO; SLN;
D O I
10.1155/2017/2120734
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The objective of this research was to formulate ciprofloxacin (CIP) in solid lipid nanoparticles (SLNs) in an attempt to develop a controlled drug delivery system. An ultrasonic melt-emulsification method was used for preparing CIP-loaded SLNs. Key findings included that SLNs were successfully produced with average particle sizes ranging from 165 to 320 nm and polydispersity index in the range of 0.18-0.33. High entrapment efficiency values were reported in all formulations. The atomic force scanning microscopic images showed spherical shape with the size range closer to those found by the particle size analyzer. CIP release exhibited controlled-release behavior with various lipids. Ciprofloxacin solid lipid nanoparticles formula containing stearic acid (CIPSTE) displayed the strongest burst effect and the most rapid release rate. The release data revealed a better fit to the Higuchi diffusion model. After storing the CIPSTE formula at room temperature for 120 days, no significant difference in particle size and zeta potential was found. CIP-loaded SLNs exhibited superior antibacterial activity. Incorporation of CIP into SLNs leads to controlled release and a superior antibacterial effect of CIP.
引用
收藏
页数:9
相关论文
共 38 条
[1]   Trends in bacterial resistance to fluoroquinolones [J].
Acar, JF ;
Goldstein, FW .
CLINICAL INFECTIOUS DISEASES, 1997, 24 :S67-S73
[2]   Diclofenac sodium delivery to the eye:: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct [J].
Attama, Anthony A. ;
Reichl, Stephan ;
Mueller-Goymann, Christel C. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 355 (1-2) :307-313
[3]   Fluoroquinolones: Mechanism of action, classification, and development of resistance [J].
Blondeau, JM .
SURVEY OF OPHTHALMOLOGY, 2004, 49 :S73-S78
[4]   Crystallization tendency and polymorphic transitions in triglyceride nanoparticles [J].
Bunjes, H ;
Westesen, K ;
Koch, MHJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 129 (1-2) :159-173
[5]   In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel [J].
Chen, DB ;
Yang, TZ ;
Lu, WL ;
Zhang, Q .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2001, 49 (11) :1444-1447
[6]   Formulation and Targeting Efficiency of Cisplatin Engineered Solid Lipid Nanoparticles [J].
Doijad, R. C. ;
Manvi, F. V. ;
Godhwani, D. M. ;
Joseph, R. ;
Deshmukh, N. V. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 70 (02) :203-207
[7]   CIPROFLOXACIN IN GENERAL-PRACTICE [J].
DONALDSON, PMW ;
PALLETT, AP ;
CARROLL, MP .
BRITISH MEDICAL JOURNAL, 1994, 308 (6941) :1437-1437
[8]   Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30 [J].
El-Badry, M ;
Fathy, M .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2006, 32 (02) :141-150
[9]  
Gandomi N, 2012, J NANOSCI LETT, V2, P21
[10]   Nanoparticles for drug delivery: The need for precision in reporting particle size parameters [J].
Gaumet, Marie ;
Vargas, Angelica ;
Gurny, Robert ;
Delie, Florence .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 69 (01) :1-9